Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

IMPAKT 2012

3 - 5 May 2012
De Rode Hoed, Amsterdam, Netherlands
Recent developments in neoadjuvant therapy
Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany
Recent developments in neoadjuvant therapy ( Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany )
17 May 2012
Highlights and goals of IMPAKT 2012
Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium
Highlights and goals of IMPAKT 2012 ( Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium )
17 May 2012
PI3K and the heterogeneity of small tumour breast cancer
Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium
PI3K and the heterogeneity of small tumour breast cancer ( Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium )
17 May 2012
Molecularly characterising triple negative breast cancer
Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium
Molecularly characterising triple negative breast cancer ( Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium )
17 May 2012
Endocrine therapy and endocrine resistant breast cancer
Prof Mitch Dowsett – The Institute for Cancer Research, London, UK
Endocrine therapy and endocrine resistant breast cancer ( Prof Mitch Dowsett – The Institute for Cancer Research, London, UK  )
17 May 2012
Neoadjuvant therapy and PCR through chemotherapy prior to surgery
Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium
Neoadjuvant therapy and PCR through chemotherapy prior to surgery ( Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium )
17 May 2012
Minimising recurrence by using most effective treatment
Prof Fabrice Andre – Institut Gustave Roussy, Paris, France
Minimising recurrence by using most effective treatment ( Prof Fabrice Andre – Institut Gustave Roussy, Paris, France )
17 May 2012
Overcoming drug resistance and targeting critical pathways
Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA
Overcoming drug resistance and targeting critical pathways ( Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA )
17 May 2012
Heterogeneity of tumours and the challenges of biomarker development
Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy
Heterogeneity of tumours and the challenges of biomarker development ( Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy )
17 May 2012
Targeting the PI3K/mTOR pathway
Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA
Targeting the PI3K/mTOR pathway ( Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA )
17 May 2012
Use of metformin against breast cancer
Prof Alastair Thompson – University of Dundee, UK
Use of metformin against breast cancer  ( Prof Alastair Thompson – University of Dundee, UK )
17 May 2012
Cancer genes differ in different parts of a tumour
Prof Charles Swanton - CRUK London Research Institute and UCL, UK
Cancer genes differ in different parts of a tumour ( Prof Charles Swanton - CRUK London Research Institute and UCL, UK )
17 May 2012
Targeting DNA damage response and repair excluding PARP for triple negative brea...
Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden
Targeting DNA damage response and repair excluding PARP for triple negative breast cancer ( Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden )
17 May 2012
Endocrine therapy resistance and next generation sequencing
Prof Matthew Ellis - Washington University, USA
Endocrine therapy resistance and next generation sequencing ( Prof Matthew Ellis - Washington University, USA )
17 May 2012
Molecular characterisation of breast cancer: the mutational landscape
Prof Sam Aparicio - University of British Columbia, Vancouver, Canada
Molecular characterisation of breast cancer: the mutational landscape ( Prof Sam Aparicio - University of British Columbia, Vancouver, Canada )
17 May 2012
New cyclin-dependent kinase inhibitor with letrozole for ER+/HER2- breast cancer
Prof Richard Finn - Universtity of California, Los Angeles, USA
New cyclin-dependent kinase inhibitor with letrozole for ER+/HER2- breast cancer ( Prof Richard Finn - Universtity of California, Los Angeles, USA )
17 May 2012
Metabolism in malignant tumors: a new approach for treating breast cancer
Prof Tak Mak - University of Toronto, Canada
Metabolism in malignant tumors: a new approach for treating breast cancer ( Prof Tak Mak - University of Toronto, Canada )
17 May 2012
Criteria required before implementation of whole genome arrays in clinical pract...
Prof Daniel Hays - University of Michigan, Ann Arbor, USA
Criteria required before implementation of whole genome arrays in clinical practice ( Prof Daniel Hays - University of Michigan, Ann Arbor, USA )
17 May 2012
Evidence for TORC1 activation marker as a predictive factor for everolimus effic...
Dr Thomas Bachelot - Centre Leon Berard, Lyon, France
Evidence for TORC1 activation marker as a predictive factor for everolimus efficacy in metastatic breast cancer ( Dr Thomas Bachelot - Centre Leon Berard, Lyon, France )
17 May 2012
Prognostic significance of progesterone receptor-positive tumour cells within lu...
Dr Aleix Prat - University of North Carolina, USA
Prognostic significance of progesterone receptor-positive tumour cells within luminal A breast cancer ( Dr Aleix Prat - University of North Carolina, USA )
17 May 2012